Imperva (IMPV) Issues Q2 Profit Warning

Go back to Imperva (IMPV) Issues Q2 Profit Warning

Imperial Capital Reiterates Outperform on Imperva (IMPV) Following 2Q Preliminary Results

July 13, 2016 7:10 AM UTC

Imperial Capital reiterated an Outperform rating and $55.00 price target on Imperva (NYSE: IMPV) following the company's 2Q preliminary results. IMPV reported preliminary revenue of $57.5-58.0mn and adjusted net loss per share of ($0.20)-
($0.22). Results came in below Street revenue estimates of... More

Nomura Securities Cuts Price Target on Imperva (IMPV) Following Preliminary 2Q Results

July 12, 2016 7:42 AM UTC

Nomura Securities maintained a Buy rating on Imperva (NYSE: IMPV), and cut the price target to $55.00 (from $60.00), following the company's preliminary 2Q financial results. IMPV is expecting revenue to be in the range of $57.5-58.0mn, an 8% growth yoy. This is down from the previous revenue... More

Oppenheimer Remains Bullish on Imperva (IMPV) Following a Disappointing 2Q Pre-Announcement

July 12, 2016 7:33 AM UTC

Oppenheimer reiterated an Outperform rating and $60.00 price target on Imperva (NYSE: IMPV) following the company's 2Q pre-announcement. Revenue was guided in the range of $57.5-58M from previous guidance of $65.5-66.5M. LPS was guided $(0.20)-(0.22) from $(0.02)-(0.04). IMPV's weak performance was primarily driven by customers'... More

Deutsche Bank Downgrades Imperva (IMPV) to Hold

July 12, 2016 6:39 AM UTC

Deutsche Bank downgraded Imperva (NYSE: IMPV) from Buy to Hold with a price target of $43.00 (from $45.00). The change follow disappointing preliminary Q2 results.

"IMPV negatively pre-announced its Q216 numbers, and blamed longer sales cycles and smaller deals sizes for the weakness in... More